TABLE 3.
CD200 expression reported in similar studies.
| CD200 expression | ||||
|---|---|---|---|---|
| Study | Total No of cases | CLL cases | MCL cases | HCL cases |
| [35] | 50 | 30/30 (100%) | — | 5/5 (100%) |
| Poongodo R et al., 2018 | 77 | 54/54 (100%) | 1/6 (16%) | 5/5 (100%) |
| [28] | 160 | 98/98 (100%) | 0/24 (0%) | 6/6 (100%) |
| Gorczynski et al., 2017 | 70 | 45/45 (100%) | 0/14 (0%) | — |
| Mason et al., 2017 | 79 | — | — | 34/34 (100%) |
| Fan L et al., 2015 | 374 | 268/271 (98.8%) | 1/31 (3%) | 2/5 (40%) |
| El-Sewefy DA et al., 2014 | 40 | 30/30 (100%) | 0/10 (0%) | — |
| [53] | 159 | 56/56 (100%) | 0/14 (0%) | 13/13 (100%) |
| [54] | 364 | 119/119 (100%) | 3/61 (5%) | 7/7 (100%) |
| [52] | 180 | 27/27 (100%) | 0/14 (0%) | 10/10 |
| [34] | 107 | 19/19 (100%) | 0/4 (0%) | — |
CLL, chronic lymphocytic leukaemia; MCL, mantle cell lymphoma; HCL, hairy cell leukaemia.